Extracorporeal apheresis therapy for Alzheimer disease-targeting lipids, stress, and inflammation
| Autor: | Karin Voit-Bak, Stefan R. Bornstein, Ulrike Schatz, Julio Licinio, Sandrine Thuret, Bernhard O. Boehm, George P. Chrousos, Richard Straube, Andrew V. Schally, Sergey Tselmin, Gerd Kempermann, Ma-Li Wong, Heinz Reichmann, Peter Rosenthal, Ulrich Julius |
|---|---|
| Přispěvatelé: | University of Zurich, Bornstein, Stefan R |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Apolipoprotein E 10265 Clinic for Endocrinology and Diabetology 2804 Cellular and Molecular Neuroscience 610 Medicine & health Inflammation Proinflammatory cytokine 2738 Psychiatry and Mental Health 03 medical and health sciences Cellular and Molecular Neuroscience chemistry.chemical_compound 0302 clinical medicine Alzheimer Disease physiopathology [Stress Psychological] 1312 Molecular Biology medicine Humans ddc:610 Molecular Biology metabolism [Inflammation] therapy [Alzheimer Disease] business.industry Cholesterol blood [Lipoproteins LDL] Cholesterol LDL blood [Cholesterol LDL] Lipid Metabolism medicine.disease Lipids physiology [Lipids] Lipoproteins LDL Psychiatry and Mental health 030104 developmental biology Apheresis chemistry Low-density lipoprotein Immunology Blood Component Removal medicine.symptom Alzheimer's disease business physiology [Lipid Metabolism] Stress Psychological 030217 neurology & neurosurgery Lipoprotein methods [Blood Component Removal] |
| Zdroj: | Molecular psychiatry 25(2), 275-282 (2019). doi:10.1038/s41380-019-0542-x |
| Popis: | Current therapeutic approaches to Alzheimer disease (AD) remain disappointing and, hence, there is an urgent need for effective treatments. Here, we provide a perspective review on the emerging role of "metabolic inflammation" and stress as a key factor in the pathogenesis of AD and propose a novel rationale for correction of metabolic inflammation, increase resilience and potentially slow-down or halt the progression of the neurodegenerative process. Based on recent evidence and observations of an early pilot trial, we posit a potential use of extracorporeal apheresis in the prevention and treatment of AD. Apolipoprotein E, lipoprotein(a), oxidized LDL (low density lipoprotein)'s and large LDL particles, as well as other proinflammatory lipids and stress hormones such as cortisol, have been recognized as key factors in amyloid plaque formation and aggravation of AD. Extracorporeal lipoprotein apheresis systems employ well-established, powerful methods to provide an acute, reliable 60-80% reduction in the circulating concentration of these lipid classes and reduce acute cortisol levels. Following a double-membrane extracorporeal apheresis in patients with AD, there was a significant reduction of proinflammatory lipids, circulating cytokines, immune complexes, proinflammatory metals and toxic chaperones in patients with AD. On the basis of the above, we suggest designing clinical trials to assess the promising potential of such "cerebropheresis" treatment in patients with AD and, possibly, other neurodegenerative diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|